Capital markets; Compliance; Technology, media and telecommunications; Healthcare & life sciences
Ouyang Dan is a partner in the Beijing and Hong Kong offices of Wilson Sonsini, where she leads the capital markets practice in the Greater China area.
Since joining the firm in 2015, Ouyang has led the team to become a major Hong Kong and US capital markets powerhouse that competes head-to-head with other well-established players in the Greater China market in the sectors of TMT, life sciences, healthcare, consumer products, and property management.
Her experience includes US and Hong Kong equity offerings, Rule 144A and Reg S bond offerings, SPAC and de-SPAC transactions, and private equity and M&A transactions. She has an impressive track record in the US and Hong Kong equity offerings for major international issuers and underwriters.
Ouyang has represented corporate clients across a wide spectrum of industries, including TMT, healthcare, education, consumer products and property management. In recent years, she has advised a leading clear aligner treatment solution provider in China in its landmark Hong Kong IPO deal with a market cap reaching USD10 billion, and advised a number of leading tech companies’ US IPOs.
Ouyang is highly active and well recognised in market-leading work in the capital markets practice in Asia. Her recent recognition and honours include Dealmakers of Asia 2021 and 2022, Super 50 TMT Lawyers 2022 and Top 15 Female Lawyer in China 2021 by Thomson Reuters ALB, and the Highly Regarded lawyer in capital markets in 2021 and 2022 by IFLR1000. She was also shortlisted as the Dealmaker of the Year (International) in 2021 and 2022 by ALB China Law Awards, as the IPO Lawyer of the Year for The Asia Legal Awards in 2022 by Law.com International, and as the International Dealmaker of the Year in 2022 by China Law & Practice Awards.